BVS
What one share of Bioventus holds
Surgical and Medical Instruments and Apparatus
We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing musculoskeletal challenges through a diverse portfolio of high-quality, innovative, and clinically-proven solutions.
Bioventus’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-27; the balance sheet is as of 2026-06-27.
| Sales | $8.34 |
|---|---|
| Profit | $0.78 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | $1.35 |
| Cash and investments | $0.43 |
| Debt | $3.80 |
| Book value | $3.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $8.34 | −$2.59 | $0.02 | −$0.24 | — | $5.30 |
| 2023 | $8.18 | −$2.49 | $0.12 | $0.13 | — | $2.77 |
| 2024 | $8.88 | −$0.56 | $0.02 | $0.59 | — | $2.29 |
| 2025 | $8.24 | $0.33 | $0.04 | $1.05 | — | $2.76 |